3 Asymmetric Stocks Hiding in Plain Sight (December 2025)

Most investors treat December as a time to tune out... maybe do some tax-loss harvesting and wait for January. In the oncology sector, that is a mistake. December is actually the busiest month of the year. It’s the "Super Bowl" of cancer research. We have the ASH Annual Meeting and the San Antonio Breast Cancer Symposium happening back-to-back.

Historically, this is when valuations get re-rated overnight. Data drops, "standard of care" shifts, and the market scrambles to catch up. I’m not interested in playing the lottery on random penny stocks. I went looking for the outliers... the companies that win regardless of the noise.

I have a very specific way of filtering these companies. I don't rely on gut feeling alone. If you're new to my analysis process, I use a specific framework to filter noise... check out my 10x Stock Checklist: My Exact 47-Point Analysis Framework. It helps me strip away the marketing fluff and focus on the actual business mechanics.

Here is what made the cut for December 2025.

The market currently looks at Immunocore and sees a "one-trick pony." They successfully commercialized Kimmtrak for uveal melanoma, which is a niche indication. The stock has drifted because investors are bored. They want the next big thing.

That boredom is exactly why I like it. Immunocore is the leader in T-cell receptor (TCR) technology. They have already proven the platform works. The "asymmetry" here isn't about what they are already selling... it's about what's coming next. They are presenting data on their PRAME platform at ASH. If this data validates their approach for broad solid tumors like ovarian or lung cancer, the addressable market expands significantly. The market is pricing them for the niche, but the potential is in the platform.

• Market Cap: ~$1.8 Billion
• Primary Product: Kimmtrak (Commercial)
• Revenue Growth: +29% YoY (Q3 '25)
• Cash Runway: Into 2026
• Catalyst: PRAME data presentation at ASH (Dec 7th)

The financials looked good, but I had to be sure. So I ran it through my 10x Stock Checklist: My Exact 47-Point Analysis Framework... and it passed the "Management Integrity" check with flying colors because they haven't diluted shareholders unnecessarily.

This is the most interesting setup on the board right now. Kura just got FDA approval for Komzifti in November. Usually, this triggers a "sell the news" event where the stock dumps. We are seeing a bit of that, but the fundamentals are shifting.

They have a monopoly on a specific genetic subset of leukemia (NPM1-mutant). They are currently in the "Valley of Death"—that awkward silence between getting approved and actually showing revenue on the earnings call. However, the CEO bought 50,000 shares on the open market back in September. When insiders buy before a launch, I pay attention.

This one is volatile. Before I even think about buying, I go to TradingView (/tradingview). I set my indicators to the Weekly view to see the bigger picture. I don't trust the numbers blindly. I pull up the chart on TradingView to check the Volume Profile to see where the institutional support is sitting. If you aren't using their advanced charts yet, you should... it saves me hours of headaches. I use the Screener (/tradingview-screener) to filter for "Market Cap < 2B" and "Rel Vol > 2". It's the easiest way to spot momentum before the news does.

• Market Cap: ~$1.0 Billion
• Status: Commercial Launch (Nov 2025)
• Insider Activity: CEO bought 50k shares
• Risk: Execution risk. They have to sell the drug now.

If Kura and Immunocore are the gold miners, Tempus sells the shovels. Or more accurately, they sell the maps. Tempus isn't a drug developer; they are a technology company that sequences tumors and uses AI to match patients to clinical trials.

I like this because it removes the binary risk of a drug trial failing. Whether a drug works or fails, pharmaceutical companies still need Tempus's data to find the patients. Their revenue growth is absurd compared to the rest of the sector. While everyone else is cutting costs, Tempus is scaling. They are becoming the operating system for oncology.

• Market Cap: ~$12.1 Billion
• Moat: Massive proprietary data library
• Revenue Growth: +84.7% YoY (Q3 '25)
• Gross Margin: 63.6%
• Risk: High cash burn rate (-$80M/quarter)

📚 Recommended Resources

10x Stock Checklist: My 47-point System

6 Simple Steps Spotting Undervalued Stocks

Earn $500/Month with Dividend Stocks

3 Swing Trading Strategies for Predictable Gains

I want to be clear... I could be wrong. Biotech is brutal. Immunocore's new data could be underwhelming. Kura's sales team might struggle to get doctors to prescribe the new drug. Tempus might burn through cash faster than they can grow.

There is no such thing as a "safe" stock in this sector. We are dealing with biology, and biology is unpredictable.

I am watching Kura (KURA) closest. If the post-approval dip settles and I see a base forming on the chart, I will look to enter. The downside seems capped given the cash on hand and the approved product, while the upside on a successful launch is multiples of the current price.

For Immunocore (IMCR), I am holding through the December conference. I believe the market is underestimating the PRAME data.

December 2025 is going to be noisy. Stick to the data.

Before you open a position, make sure it passes your own sniff test. Download my 10x Stock Checklist to run the full audit yourself.